Pharvaris (NASDAQ:PHVS – Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, April 9th. Analysts expect Pharvaris to post earnings of ($0.74) per share for the quarter.
Pharvaris Stock Performance
Shares of Pharvaris stock opened at $14.83 on Wednesday. The firm has a 50-day simple moving average of $16.59 and a two-hundred day simple moving average of $18.83. Pharvaris has a fifty-two week low of $14.14 and a fifty-two week high of $25.50. The company has a market cap of $775.46 million, a P/E ratio of -5.30 and a beta of -3.02.
Wall Street Analysts Forecast Growth
Separately, JMP Securities increased their price target on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, January 31st.
About Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
- Five stocks we like better than Pharvaris
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- How to trade penny stocks: A step-by-step guide
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
